Home/Filings/4/0001127602-22-009795
4//SEC Filing

Grossi Federico 4

Accession 0001127602-22-009795

CIK 0001492422other

Filed

Mar 16, 8:00 PM ET

Accepted

Mar 17, 6:19 PM ET

Size

8.0 KB

Accession

0001127602-22-009795

Insider Transaction Report

Form 4
Period: 2022-03-15
Grossi Federico
See Remarks
Transactions
  • Exercise/Conversion

    Common Stock

    2022-03-15$4.31/sh+7,000$30,170116,811 total
  • Sale

    Common Stock

    2022-03-15$39.57/sh375$14,839116,436 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-03-157,00050,723 total
    Exercise: $4.31Exp: 2027-08-20Common Stock (7,000 underlying)
Footnotes (2)
  • [F1]This is a scheduled sale from 10B5-1 trading plan.
  • [F2]This stock option was granted on 08/21/2017 and is fully vested.

Issuer

Apellis Pharmaceuticals, Inc.

CIK 0001492422

Entity typeother

Related Parties

1
  • filerCIK 0001720634

Filing Metadata

Form type
4
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 6:19 PM ET
Size
8.0 KB